Therapeutic applications of group I intron‐based trans‐splicing ribozymes

Since the breakthrough discovery of catalytic RNAs (ribozymes) in the early 1980s, valuable ribozyme‐based gene therapies have been developed for incurable diseases ranging from genetic disorders to viral infections and cancers. Ribozymes can be engineered and used to downregulate or repair pathogenic genes via RNA cleavage mediated by trans ‐cleaving ribozymes or repair and reprograming mediated by trans ‐splicing ribozymes, respectively. Uniquely, trans ‐splicing ribozymes can edit target RNAs via simultaneous destruction and repair (and/or reprograming) to yield the desired therapeutic RNAs, thus selectively inducing therapeutic gene activity in cells expressing the target RNAs. In contrast to traditional gene therapy approaches, such as simple addition of therapeutic transgenes or inhibition of disease‐causing genes, the selective repair and/or reprograming abilities of trans ‐splicing ribozymes in target RNA‐expressing cells facilitates the maintenance of endogenous spatial and temporal gene regulation and reduction of disease‐associated transcript expression. In molecular imaging technologies, trans ‐splicing ribozymes can be used to reprogram specific RNAs in living cells and organisms by the 3′‐tagging of reporter RNAs. The past two decades have seen progressive improvements in trans ‐splicing ribozymes and the successful application of these elements in gene therapy and molecular imaging approaches for various pathogenic conditions, such as genetic, infectious, and malignant disease. This review provides an overview of the current status of trans ‐splicing ribozyme therapeutics, focusing on Tetrahymena group I intron‐based ribozymes, and their future prospects. This article is categorized under: RNA in Disease and Development > RNA in Disease